Congress Receives FDA’s User Fee Reauthorization Recommendations

The HHS secretary recently delivered FDA’s recommendations for reauthorizing user fees covering prescriptions, generic drugs and biosimilars to Congress, before the body begins to craft a legislation package due by the end of September.

Congress must pass three laws reauthorizing fees for prescription drugs, generics, and biosimilars before Oct. 1. This year’s reauthorization will be effective through fiscal 2022.